Value of Urine Peptides in Assessing Kidney and Cardiovascular Disease
PROTEOMICS – Clinical Applications · 2021-01 · 15 (1)
DOI: 10.1002/prca.202000027 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift PROTEOMICS – Clinical Applications, online erschienen am 16.08.2020. Verfasst von Agnieszka Latosinska und 5 weiteren Autor:innen. Beteiligte Einrichtung: Mosaiques Diagnostics GmbH, Rotenburger Straße 20, 30659, Hannover, Germany. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Biomarkers, Peptides. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 86 Literaturangaben. Gefördert von: Fondation pour la Recherche Médicale, Agence Nationale de la Recherche, Bundesministerium für Bildung und Forschung.
Abstract (Originalsprache)
Urinary peptides gained significant attention as potential biomarkers especially in the context of kidney and cardiovascular disease. In this manuscript the recent literature since 2015 on urinary peptide investigation in human kidney and cardiovascular disease is reviewed. The technology most commonly used in this context is capillary electrophoresis coupled mass spectrometry, in part owed to the large database available and the well‐defined dataspace. Several studies based on over 1000 subjects are reported in the recent past, especially examining CKD273, a classifier for assessment of chronic kidney disease based on 273 urine peptides. Interestingly, the most abundant urinary peptides are generally collagen fragments, which may have gone undetected for some time as they are typically modified via proline hydroxylation. The data available suggest that urinary peptides specifically depict inflammation and fibrosis, and may serve as a non‐invasive tool to assess fibrosis, which appears to be a key driver in kidney and cardiovascular disease. The recent successful completion of the first urinary peptide guided intervention trial, PRIORITY, is expected to further spur clinical application of urinary peptidomics, aiming especially at early detection of chronic diseases, prediction of progression, and prognosis of drug response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mosaiques Diagnostics GmbH, Rotenburger Straße 20, 30659, Hannover, Germany.
- Département de Néphrologie et Transplantation d'organes, Centre de référence des maladies rénales rares, Centre Hospitalier Universitaire de Toulouse, 1, Avenue Jean Poulhes, Toulouse, 31059, France.
- Institut National de la Santé et de la Recherche Médicale (INSERM), U1048, Institut of Cardiovascular and Metabolic Disease, 1 Avenue Jean Poulhès, BP 84225, Toulouse Cedex 4, 31432, France.
- Université Toulouse III Paul-Sabatier, Route de Narbonne, Toulouse, 31330, France.
- Department of Nephrology and Kuratorium for Dialysis and Transplantation Renal Unit, Hospital St Georg, Delitzscher Str. 141, 04129, Leipzig, Germany.
- Department of Nephrology, Martin-Luther-University Halle/Wittenberg, Universitätsplatz 10, 06108, Halle (Saale), Germany.
ORCID-Profile: Justyna Siwy, Harald Mischak, Joost P Schanstra
Förderung
- Fondation pour la Recherche Médicale
- Agence Nationale de la Recherche
- Bundesministerium für Bildung und Forschung
Zitieren
APA
Latosinska, A., Siwy, J., Faguer, S., Beige, J., Mischak, H., & Schanstra, J. P. (2021). Value of Urine Peptides in Assessing Kidney and Cardiovascular Disease. PROTEOMICS – Clinical Applications, 15(1). https://doi.org/10.1002/prca.202000027
Vancouver
Latosinska A, Siwy J, Faguer S, Beige J, Mischak H, Schanstra JP. Value of Urine Peptides in Assessing Kidney and Cardiovascular Disease. PROTEOMICS – Clinical Applications. 2021;15(1). doi:10.1002/prca.202000027
BibTeX
@article{Latosinska2021,
author = {Latosinska, Agnieszka and Siwy, Justyna and Faguer, Stanislas and Beige, Joachim and Mischak, Harald and Schanstra, Joost P},
title = {Value of Urine Peptides in Assessing Kidney and Cardiovascular Disease},
journal = {PROTEOMICS – Clinical Applications},
year = {2021},
volume = {15},
number = {1},
doi = {10.1002/prca.202000027}
}
EUVIMED